Research programme: cancer immunotherapies - Arcus Biosciences

Drug Profile

Research programme: cancer immunotherapies - Arcus Biosciences

Alternative Names: LAG-3 antibody-Arcus Biosciences; STING targeting candidates-Arcus Biosciences; TIM-3 antibody-Arcus Biosciences; TLR4 targeting candidates-Arcus Biosciences

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Arcus Biosciences
  • Class Antibodies; Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators; MPYS-protein-stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 19 Sep 2017 Arcus Biosciences and Taiho Pharmaceutical enter into option and license agreement to develop and commercialise immunotherapies for Cancer in Asia, including Japan and excluding China
  • 19 Sep 2017 Arcus Biosciences plans a clinical trials of its immunotherapies for Cancer in 2018
  • 28 Aug 2017 Preclinical trials in Cancer in USA (Parenteral) before August 2017 (Arcus Biosciences pipeline, August 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top